Association of a change in immunosuppressive regimen with hemodynamic and inflammatory markers of cardiovascular disease after kidney transplantation

American Journal of Hypertension

Volumn 26, Issue 7, 2013, Pages 843-849

  Yong, Kenneth ^a,b   Nguyen, Hung Do ^a,b   Hii, Lawrence ^a   Chan, Doris T ^a   Boudville, Neil ^a,b   Messineo, Adriana ^a   Lim, Ee Mun ^a   Dogra, Gursharan K ^a   Lim, Wai H ^a,b  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

blood pressure; calcineurin inhibitor; everolimus; hypertension; interleukins; renal transplant; sirolimus; vascular function

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 6; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS;

ADULT; ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIET RESTRICTION; DISEASE MARKER; FEMALE; GLUCOSE BLOOD LEVEL; GRAFT RECIPIENT; HEART RATE; HEMODYNAMIC MONITORING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE WAVE;

BLOOD PRESSURE; CALCINEURIN INHIBITOR; EVEROLIMUS; HYPERTENSION; INTERLEUKINS; RENAL TRANSPLANT; SIROLIMUS; VASCULAR FUNCTION.;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HEMODYNAMICS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84878869723     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt017     Document Type: Article

References (22)

1. Wolfe R, Ashby V, Milford E, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341:1725-1730.
2. Meier-Kriesche H,Schold J, Srinivas T, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4:378-383.
3. Pilmore H, Dent H, Chang S, McDonald S, Chadban S. Reduction in cardiovascular death after kidney transplantation. Transplantation.2010; 89:851-857.
4. Webber A, Hirose R, Vincenti F. Novel strategies in immunosuppression: issues in perspective. Transplantation 2011; 91:1057-1064.
5. Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F; ZEUS Study Investigators. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011; 377:837-847.
6. Lebranchu Y, Thierry A, Toupance O, Westeel PF, Etienne I, Thervet E, Moulin B, Frouget T, Le Meur Y, Glotz D, Heng AE, Onno C, Buchler M, Girardot-Seguin S, Hurault de Ligny B. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009; 9:1115-1123.
7. Paoletti E, Amidone M, Cassottana P, Gherzi M, Marsano L, Cannella G. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial. Am J Kidney Dis 2008; 52:324-330.
8. Seckinger J, Sommerer C, Hinkel U, Hoffmann O, Zeier M, Schwenger V. Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. J Hypertens 2008; 26:2213-2219.
9. Paoletti E, Marsano L, Bellino D, Cassottana P, Cannella G. Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial. Transplantation 2012; 93:503-508.
10. Libetta C, Sepe V, Zucchi M, Portalupi V, Meloni F, Rampino T, Dal Canton A. The effect of sirolimus-or cyclosporine-based immunosuppression effects on T-cell subsets in vivo. Kidney Int 2007; 72:114-120.
11. Johnston O, Rose C, Webster A, Gill J. Sirolimus is associated with newonset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19:1411-1418.
12. Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470.
13. Verbeke F, Marechal C, Van Laecke S, Van Biesen W, Devuyst O, Van Bortel LM, Jadoul M, Vanholder R. Aortic stiffness and central wave reflections predict outcome in renal transplant recipients. Hypertension 2011; 58:833-838.
14. Weber T, Ammer M, Gunduz D, Bruckenberger P, Eber B, Wallner M. Association of increased arterial wave reflections with decline in renal function in chronic kidney disease stages 3 and 4. Am J Hypertens 2011; 24:762-769.
15. Hermans M, Henry R, Dekker J, Kooman JP, Kostense PJ, Nijpels G, Heine RJ, Stehouwer CD. Estimated glomerular filtration rate and urinary albumin excretion are independently associated with greater arterial stiffness: the Hoorn Study. J Am Soc Nephrol 2007; 18: 1942-1952.
16. Seibert F, Behrendt C, Schmidt S, van der Giet M, Zidek W, Westhoff T. Differential effects of cyclosporine and tacrolimus on arterial function. Transpl Int 2011; 24:708-715.
17. Jefferis B, Papacosta O, Owen C, Wannamethee SG, Humphries SE, Woodward M, Lennon LT, Thomson A, Welsh P, Rumley A, Lowe GD, Whincup PH. Interleukin 18 and coronary heart disease: prospective study and systematic review. Atherosclerosis 2011; 217:227-233.
18. Tellides G, Pober J. Interferon-gamma axis in graft arteriosclerosis. Circ Res 2007; 100:622-632.
19. Ko H, Hambly B, Eris J, Levidiotis V, Wyburn K, Wu H, Chadban SJ, Yin JL. Dentritic cell derived IL-18 production is inhibited by rapamycin and sanglifehrin A, but not cyclosporine A. Transplant Immunol 2008; 20:99-105.
20. Takahashi H, Mori S, Iwagaki H, Yoshino T, Tanaka N, Nishibori M. Simvastatin induces interleukin-18 production in human peripheral blood mononuclear cells. Clin Immunol 2005; 116:211-216.
21. Schena F, Pascoe M, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF; Sirolimus CONVERT Trial Study Group. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-242.
22. Teutonico A, Schena P, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005; 16:3128-3135.